RxDoctor Payments Data

Gary Sharpless, MD

Internal Medicine · Conroe, TXNPI 1982792883

Payments from drug & device makers

$2,134in general payments, 2019–2025

Across 127 payments — averaging $16.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$819
  • Lilly USA, LLC$175
  • Novo Nordisk$172
  • AbbVie$118
  • Mylan Specialty L.p.$102
  • Abbott$97
  • plus $651 from 22 others

What the payments were for

  • Food & beverage$2,134100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,134 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$160,449
Medicare patients
402
Services billed
59,537

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide143$165,305
MounjaroTirzepatide118$137,538
FarxigaDapagliflozin Propanediol96$83,231
EliquisApixaban78$75,453
JanuviaSitagliptin Phosphate21$24,771
Np ThyroidThyroid,pork232$18,197
Xigduo XrDapaglifloz Propaned/Metformin20$17,248
Liothyronine Sodium299$14,245
XareltoRivaroxaban11$13,859
ProgesteroneProgesterone, Micronized279$12,514
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$11,566
RybelsusSemaglutide12$9,897
PremarinEstrogens, Conjugated14$6,940
MyrbetriqMirabegron16$5,525
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen188$4,206

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$172$175,201155 claims
Lilly USA, LLCMounjaro$175$137,538118 claims
AstraZenecaFarxiga$819$83,23196 claims
PfizerEliquis, Premarin$75$82,39392 claims
MerckJanuvia$27$24,77121 claims
Acella Pharmaceuticals, LLCNp Thyroid$18$18,197232 claims
Johnson & JohnsonXarelto$25$13,85911 claims
Astellas Pharma US IncMyrbetriq$15$5,52516 claims
AbbVieArmour Thyroid$118$2,38827 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Conroe

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →